• Association of Serum Interleukin-33 Levels With Clinical Manifestations in Systemic Lupus Erythematosus

  NCT07149402

  Not yet recruitingObservationalUpdated Sep 2, 2025
• IL17 in Systemic Lupus Erythematosus Patients: Association With Disease Activity and Organ Damage

  NCT05045417

  Unknown statusObservationalUpdated Sep 16, 2021
• Anti-infection of Low-does IL-2 in SLE

  NCT02932137

  CompletedInterventionalNot ApplicableUpdated Mar 15, 2018
• Low-dose IL-2( Interleukin-2) Treatment in SLE

  NCT02084238

  CompletedInterventionalNot ApplicableUpdated Apr 3, 2020
• IL-26 and Systemic Lupus Erythematosus

  NCT01889641

  TerminatedObservationalUpdated Sep 8, 2017
• Correlation Between Serum Uric Acid, Serum Homocysteine Level and Interleukin- 17 in Lupus Nephritis Patients

  NCT07017868

  RecruitingObservationalUpdated Jun 12, 2025

ClinicalTrials.gov ID

NCT06713187

Lead Sponsor

Sohag UniversityOTHER

Overall Status

Recruiting

Study Type

Interventional

Phase

Not Applicable

Enrollment

90Estimated

Last Update Posted

Dec 3, 2024Actual

Start Date

May 1, 2025Estimated

Primary Completion Date

Aug 1, 2025Estimated

Completion Date

Jun 1, 2026Estimated

Official Title

Role of Interleukin 23 in Systemic Lupus Erythematosus Related Interstial Lung Disease

Brief Summary

assement of interleukin 23 in serum of patients with systemic lupus erythematosus related interstial lung disease .

Detailed Description

for all patients detailed history taken clinical and rhumatological examination will be assessed and SLEDAI score will be collected from the case record of the patients&laboratory investigation included 1_erythrocytic sedimentation rate.2_complete blood count.3_interleukin23 .4_complement 3&4.5_Antinuclear Antibodies.6_Anti double stranded antibodies.7_full basic biochemical test(24 urine protien)8_high resolution computed tomography.

• Systemic Lupus Erythematosus Related Interstial Lung Disease

• interleukin 23

Ages Eligible for Study

Adult (18-64)

Sexes Eligible for Study

All

Accepts Healthy Volunteers

Yes

Eligibility Criteria

Inclusion Criteria:

• patients with systemic lupus erythematous and patients with systemic lupus erythematosus with interstial lung disease.

Exclusion Criteria:

• patients with chest conditions rather than interstial lung disease &who receiving biological blocking antibodies& those treated with immunosuppressive drugs.

Primary Purpose

Diagnostic

Allocation

Randomized

Interventional Model

Sequential Assignment

Masking

None (Open Label)

Lead Sponsor

Sohag UniversityOTHER

ethics@med.sohag.edu.eg0934602963